In the constantly evolving landscape of oncology, targeted therapy has emerged as a promising approach to combat various types of cancer. This therapy, which employs drugs or other substances to identify and attack specific cancer cells without harming normal cells, is revolutionizing cancer treatment.
Targeted therapies work on the molecular level, focusing on the changes in cancer cells that help them grow, divide, and spread. They interfere with specific molecules ("molecular targets") involved in the growth, progression, and spread of cancer. These therapies are a cornerstone of precision medicine, a form of medicine that uses information about a person’s genes and proteins to prevent, diagnose, and treat disease.
There are two main types of targeted therapies: small molecule drugs and monoclonal antibodies. Small molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells. Monoclonal antibodies are drugs that can target cell surface proteins and signals. They are too large to enter cells, so they are used for targets on the outer surface of cells.
Targeted therapies offer potential benefits over traditional forms of cancer treatment. They can be more effective, less harmful to normal cells, and often have fewer side effects. However, there are challenges to be addressed. Not all tumors have the same targets, making it difficult to find a 'one-size-fits-all' treatment. Additionally, cancer cells can become resistant to these therapies, necessitating the development of new strategies.
While targeted therapy is not without its challenges, it holds significant promise for the future of oncology. As our understanding of the molecular mechanisms of cancer improves, so too will our ability to develop more effective and less harmful treatments. Embracing targeted therapy is a step towards more personalized, effective, and tolerable cancer care.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation